Wedoany.com Report-Apr. 2, DHL Group, a logistics provider, has recently acquired full ownership of CRYOPFP, a specialty courier, from Cryoport, Inc. This move bolsters DHL’s expertise in logistics for clinical trials, biopharma, and cell and gene therapies, while fostering a strategic partnership with Cryoport to enhance supply chain services.

Oscar de Bok, CEO of DHL Supply Chain, stated: “The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint in the conventional pharma and life science healthcare segment.” He added: “The acquisition of CRYOPDP and the extended partnership with Cryoport Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities.”

CRYOPDP specializes in tailored courier services, operating in 15 countries and managing over 600,000 shipments annually. It serves customers and patients across more than 135 countries, offering high-quality logistics support. The acquisition strengthens DHL’s ability to meet growing demands in the specialty pharma sector.

Jerrell Shelton, CEO of Cryoport, commented: “We are indeed pleased to build on our trusted relationship with the DHL Group. Working together we will bring an enhanced set of supply chain solutions to meet companies’ and patients’ critical supply chain needs. This strategic partnership taps into the strong expertise of DHL’s Supply Chain and CRYOPDP, presenting a substantial opportunity for Cryoport to further expand its reach to global growth markets such as Asia Pacific (APAC) and Europe, Middle East and Africa (EMEA).”

This deal aligns with DHL’s goal to broaden its logistics network, while the collaboration with Cryoport opens new avenues for both companies to deliver reliable, comprehensive solutions worldwide.